Search results
Results from the WOW.Com Content Network
Dosage and Administration: Guidelines on how to properly administer the drug, including dosage amounts and frequency. Contraindications: Situations where the drug should not be used. Warnings and precautions: Important safety information and potential risks associated with the drug. Adverse reactions: Common and serious side effects that may occur.
o 2, o 2 both eyes "O 2" usually means oxygen or oxygen therapy: o.d. omni die: every day (once daily) (preferred to "qd" in the UK [10]) o.d. oculus dexter: right eye o can be mistaken as an a which could read "a.d.", meaning right ear, confusion with "omni die" o.m. omni mane: every morning omn. bih. omni bihora: every 2 hours omn. hor. omni ...
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage). [1] Sustained-release dosage forms are dosage ...
Dosage typically includes information on the number of doses, intervals between administrations, and the overall treatment period. [3] For example, a dosage might be described as "200 mg twice daily for two weeks," where 200 mg represents the individual dose, twice daily indicates the frequency, and two weeks specifies the duration of treatment.
Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist ( GLP-1 , GIP , and GCGR receptors). [ 1 ]
The dose schedule given every two weeks is as follows: [5] Day 1–2: Oxaliplatin 100 mg/m 2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m 2 (or levoleucovorin 200 mg/m 2) IV infusion, followed by 5-FU 400 mg/m 2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m 2 for first two cycles, and may be increased to 3000 mg/m 2 if tolerated by ...
Topical gels are commonly used as sustained release dosage forms. [5] [9] Usage of the sustained release dosage form reduces the administration of recurrent doses while maintaining serum dose levels at the therapeutic range (difference between toxic and therapeutic doses), hence improving patient compliance. [5]
Thin-film drug delivery uses a dissolving film or oral drug strip to administer drugs via absorption in the mouth (buccally or sublingually) and/or via the small intestines (enterically). A film is prepared using hydrophilic polymers that rapidly dissolves on the tongue or buccal cavity, delivering the drug to the systemic circulation via ...